Company intelligence / Profile preview

Gradientech

Uppsala, Uppsala län, Swedengradientech.se ↗

Ownership: Private
Employees: ~34
Development stage: Commercial

Overview

Gradientech’s QuickMIC® delivers minimum inhibitory concentration (MIC) values from positive blood cultures in as little as 2 hours—faster than any other phenotypic AST system. This enables rapid and precise treatment decisions for sepsis patients and supports antimicrobial stewardship by reducing unnecessary or ineffective antibiotic use. The company’s technology has demonstrated high precision and speed in clinical laboratory settings. No specific published clinical trial results are cited in the search results.

Therapeutic areas: Infectious Diseases
Modalities: Device (in vitro diagnostic system)Microfluidic platform
Industry: Pathology

Partnerships

Hardy DiagnosticsAdaHorizon 2020 programBIO-X Accelerate

Beyond the preview

Go deeper on Gradientech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gradientech.

Explore the full profile